Work

Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders

Year: 2020

Type: editorial

Abstract: Atacicept failed to show an effect in multiple sclerosis, optic neuritis, rheumatoid arthritis, and systemic lupus erythematosus."This statement is not entirely correct and should be reevaluated.Not all available data are reported in the review, particularly for SLE, and the limitations of the review are not appropriately acknowledged.A Phase III study to confirm the positive effect of atacicept in SLE patients with HDA (as observed in Phase II) is planned.

Source: Frontiers in Immunology

DOI: 10.3389/fimmu.2020.592639

Authors: David A. Isenberg, Amy H. Kao, Aida Aydemir, Joan T. Merrill

Institutions: University College London, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Oklahoma Medical Research Foundation

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,950